Get the Stockscreener App
5.75
2.21%
-0.13
After Hours:
5.75
Alvotech stock is traded at $5.75, with a volume of 705.13K.
It is down -2.21% in the last 24 hours and up +13.86% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$5.88
Open:
$5.9
24h Volume:
705.13K
Relative Volume:
0.73
Market Cap:
$2.05B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
59.65
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
-2.04%
1M Performance:
+13.86%
6M Performance:
+83.12%
1Y Performance:
-29.19%
1-Day Range:
$5.67
$5.90
1-Week Range:
$5.67
$6.06
52-Week Range:
$2.94
$9.045
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.75 | 2.05B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
ALVO Stock Price, Quote & Chart - ChartMill
Alvotech (NASDAQ:ALVO) Shares Up 3.5%Here's What Happened - MarketBeat
Alvotech (ALVO) Jumped, But What Is Driving Attention Now? - simplywall.st
Alvotech (NASDAQ:ALVO) Trading Up 7.2%Should You Buy? - MarketBeat
Can Alvotech (NASDAQ:ALVO) Change Its Healthcare Story? - Kalkine Media
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CHMP Positive Opinions for 2 Biosimilars: Alvotech/Advanz’s Omalizumab & Biocon’s Pertuzumab - Pearce IP
Positive Report for Alvotech (ALVO) from Barclays - The Globe and Mail
Why This Biotech Stock Just Got a Rare Double Upgrade - Barron's
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside - TradingView
Alvotech Jumps Most Since December After Barclays Doubles Price Target to $8 - finance.biggo.com
Alvotech Shares Rise After Double Upgrade From Barclays - marketscreener.com
Alvotech stock surges on Barclays upgrade to Overweight - Investing.com
Alvotech stock surges on Barclays upgrade to Overweight By Investing.com - Investing.com South Africa
Alvotech (NASDAQ:ALVO) Shares Gap UpHere's What Happened - MarketBeat
Alvotech stock gains on double upgrade at Barclays (ALVO:NASDAQ) - Seeking Alpha
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday - Benzinga
Alvotech Price Target Raised to $8.00/Share From $4.00 by Barclays - Moomoo
Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target - Yahoo Finance
Why is Alvotech stock rallying 5% today? - Investing.com
Barclays Upgrades Alvotech(ALVO.US) to Buy Rating, Raises Target Price to $8 - Moomoo
Barclays upgrades Alvotech stock rating on FDA approval outlook - Investing.com
Certain Stock Options of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026. - marketscreener.com
How FDA Filing Acceptance Will Impact Alvotech (ALVO) Investors - simplywall.st
Certain Ordinary Shares of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026. - marketscreener.com
What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media
Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - MarketBeat
Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
Takeda Files Second Vedolizumab Biosimilar BPCIA Action with Alvotech in the Firing Line - Pearce IP
Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP
Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat
FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net
Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance
Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance
Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st
Alvotech to present at upcoming investor conferences in September - Yahoo Finance
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st
Alvotech (ALVO) Gets New ‘Buy’ Reco. Should Investors Follow? - Yahoo Finance
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - Pulse 2.0
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):